Skip to main content
. Author manuscript; available in PMC: 2018 Jul 23.
Published in final edited form as: J Neurol Neurosurg Psychiatry. 2014 Sep 22;86(7):708–713. doi: 10.1136/jnnp-2014-308736

Figure 1.

Figure 1

Schematic representation of the breakdown of patients into four clinical categories. The patients are divided into those with Positive and Low Positive initial NMDAR cell-based assays score. Cerebrospinal fluid (CSF) N-methyl-d-aspartate receptor autoantibody (NMDAR-Ab) and tumour associations (with mortality, †) are represented.